Lyme Disease, Line Blot, Cerebrospinal Fluid
Use
Detects intrathecal antibody production against Borrelia burgdorferi in cerebrospinal fluid to confirm neuroborreliosis. Serves as a confirmatory immunoblot test following evidence of Lyme disease antibody presence, specifically tailored for CSF specimens.
Special Instructions
Intended as second‑step confirmatory testing of CSF for Lyme disease following positive or equivocal EIA/IFA on serum; follow routine CSF collection/handling protocols. No special patient preparation required.
Limitations
This test may be considered investigational by Medicare and other payers and may not be covered. A line blot assay alone is insufficient for Lyme diagnosis; cross‑reactivity with other spirochetal diseases and autoimmune conditions is possible; interpret alongside serology and clinical presentation.
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
LOINC Codes
- 23979-8
- 23985-5
- 28054-5
- 28039-6
- 28048-7
- 28055-2
- 28040-4
- 28036-2
- 28053-7
- 28056-0
- 28057-8
- 48500-3
- 28043-8
- 28037-0
- 28062-8
Result Turnaround Time
3-5 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
2 mL
Minimum Volume
1 mL
Container
Sterile plastic tube
Collection Instructions
Maintain sterility and forward promptly. Send CSF refrigerated.
Patient Preparation
No special preparation is required.
Other tests from different labs that may be relevant